Search

• ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

  Media

  ViiV announced that the FDA has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg), treatment of HIV-1 infection.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-fda-approval-for-triumeq-abacavir-dolutegravir-and-lamivudine-a-new-single-pill-regimen-for-the-treatment-of-hiv-1-infection/

  First published: 22 August 2014

• ViiV Healthcare receives EU marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV

  Media

  ViiV announced, the EC has granted marketing authorisation for Triumeq® for the treatment of HIV in those aged 12+ and weighing 40kg+.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-eu-marketing-authorisation-for-triumeq-dolutegravirabacavirlamivudine-a-new-once-daily-single-pill-regimen-for-the-treatment-of-hiv/

  First published: 03 September 2014

• GSK ‘confronts COPD’ to deliver new insights from across the globe to promote improved management of chronic lung disease

  Media

  Data published today suggests, that long-term health outlook for patients with chronic obstructive pulmonary disease (COPD) has improved.

  https://www.gsk.com/en-gb/media/press-releases/gsk-confronts-copd-to-deliver-new-insights-from-across-the-globe-to-promote-improved-management-of-chronic-lung-disease/

  First published: 22 January 2015

• GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2 which does not diminish in the age groups studied

  Media

  Shingles is a significant public health burden, more than 90% of adults aged 50 years and over are at risk.

  https://www.gsk.com/en-gb/media/press-releases/gsk-candidate-vaccine-for-the-prevention-of-shingles-demonstrates-overall-efficacy-of-972-which-does-not-diminish-in-the-age-groups-studied/

  First published: 28 April 2015

• Results Announcement for the second quarter 2015

  Media

  GSK delivers Q2 Group sales of £5.9 billion +7% CER and core EPS of 17.3p (flat CER) in first full quarter of performance since transaction

  https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-second-quarter-2015/

  First published: 29 July 2015

• GSK announces regulatory submission for umeclidinium monotherapy for COPD in Japan

  Media

  GSK announced the submission of a regulatory application to the JMHLW for UMEC, a LAMA, administered using the Ellipta™ dry powder inhaler.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-regulatory-submission-for-umeclidinium-monotherapy-for-copd-in-japan/

  First published: 23 May 2014

• GSK receives US approval for once-weekly type 2 diabetes treatment, Tanzeum™ (albiglutide)

  Media

  GSK today announced that the FDA has approved TanzeumTM (albiglutide) for injection, as a once-weekly treatment for type 2 diabetes.

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-approval-for-once-weekly-type-2-diabetes-treatment-tanzeum-albiglutide/

  First published: 15 April 2014

• GSK joins with research councils in UK and South Africa to tackle non-communicable diseases in Africa

  Media

  GSK announced a £5m collaboration with UK and SAMRC, to support much-needed research into NCDs in Africa, part of GSK Open Lab initiative.

  https://www.gsk.com/en-gb/media/press-releases/gsk-joins-with-research-councils-in-uk-and-south-africa-to-tackle-non-communicable-diseases-in-africa/

  First published: 09 September 2014

• Results announcement for the third quarter 2015

  Media

  Q3 sees continued progress in execution of Group strategy Sales of £6.1 billion (+11% CER) and core EPS of 23.0p (-13% CER)

  https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-third-quarter-2015/

  First published: 28 October 2015

• Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint

  Media

  GSK announced a phase III study to assess the efficacy of HZ/su, investigational vaccine for shingles, has met its primary endpoint.

  https://www.gsk.com/en-gb/media/press-releases/pivotal-phase-iii-study-of-gsk-shingles-candidate-vaccine-meets-its-primary-endpoint/

  First published: 18 December 2014